European Pharmaceutical Review

OCTOBER 25, 2024

The biologic ZL-1310 is being investigated in an ongoing Phase Ia/Ib study in these patients who have had at least one platinum-based chemotherapy regimen. The compound was designed to address issues such as payload toxicity seen in first-generation ADC therapies, according to Zai Lab.

Chemotherapy 97

Chemotherapy Compounding Immunization 97

The FDA Law Blog

JANUARY 18, 2024

Rescheduling Recommendation, 2024 FDA’s 2023 analysis and recommendation finally came to light when Texas attorney Matt Zorn posted it on his website a week ago. whether growing or not; its seeds; resin extracted from any part; and every compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seeds or resin.

FDA 69

FDA Controlled Substances Chemotherapy Compounding 69

Blog: Ask a Student Pharmacist

JUNE 21, 2023

Jiashu Xie, PhD eomizowh Wed, 06/21/2023 - 10:11 Expand all + Biography Research Summary Current research in the Pharmacokinetics (PK) lab has focused on profiling the in vitro ADME (absorption, distribution, metabolism, and excretion) and in vivo PK properties of lead compounds from medicinal chemistry efforts.

Compounding 40

Compounding Chemotherapy Immunization 40

The Thyroid Pharmacist

SEPTEMBER 20, 2024

Chemotherapy agents: Chemotherapy agents can lead to constipation in a variety of ways such as slowing the movements of the intestinal tract or creating inflammation that disrupts digestive function. Accessed September 6, 2024. Accessed September 17, 2024. 78] This makes the stool softer and easier to pass. freece.com. [11]

Health and Personal Care Stores 75

Health and Personal Care Stores Chemotherapy Immunization Compounding 75

Pharmaceutical Technology

MARCH 29, 2023

AlgoTx remains on track to start enrolling subjects of a Phase II study of its compound ATX01 for the rare condition erythromelalgia in Q2 2023, says CEO Stéphane Thiroloix. Stéphane Thiroloix, CEO of AlgoTx Alongside erythromelalgia, the company is testing ATX01 in a Phase II study in chemotherapy-induced peripheral neuropathy (CIPN).

Chemotherapy 52

Chemotherapy Compounding Communication FDA 52

The FDA Law Blog

FEBRUARY 11, 2024

Few would oppose FDA-approved marijuana-derived medications if marijuana compounds are found to have medical value; the National Institute of Health should continue to fund research on any potential medical value of marijuana and on the harms of highly potent products. January 29, 2024).

Controlled Substances 59

Controlled Substances Chemotherapy FDA Compounding 59